课题基金 / 基金详情

The functional analysis and clinical significance of apotosis inducing factor, RCAS1

The functional analysis and clinical significance of apotosis inducing factor, RCAS1
凋亡诱导因子RCAS1的功能分析及临床意义
批准号:
12671615
负责人:
SONODA Kenzo
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

SONODA Kenzo的其他基金

相似基金

相关文献

中文摘要
翻译
本研究探讨肿瘤相关抗原RCAS - 1的功能及临床意义。RCAS1是ⅱ型膜蛋白之一,在正常外周血淋巴细胞中诱导细胞凋亡。RCAS1染色体定位于8q23,其表达受雌激素诱导。在我们前期的研究中,RCAS1在子宫癌和卵巢癌中均有强表达,且RCAS1的表达与子宫癌患者预后不良显著相关。(1)为了阐明RCAS1在肿瘤行为中的生物学作用,我们通过免疫组化分析了RCAS1表达与肿瘤间质细胞反应之间的关系。在肿瘤转移淋巴结中,RCAS1表达的子宫癌患者T淋巴细胞凋亡指数明显升高。在肿瘤细胞周围结缔组织中,RCAS1表达患者的vimentin表达细胞显著减少。而Fas-L和TNF-a的表达与肿瘤基质中T淋巴细胞的tic指数和结缔组织中vimentin表达的细胞数量无关。基于这些发现,RCAS1的表达通过降低免疫反应和结缔组织反应在肿瘤侵袭性获得中起着关键作用。(2)检查RCAS1表达与子宫内膜肿瘤进展的关系,在腺癌中RCAS1表达明显高于正常和增生子宫内膜。此外,RCAS1在3级患者中的检测频率高于1级和2级患者。这些结果提示RCAS1的表达可能与子宫内膜腺癌的恶性转化和分化不良有关。(3)研究rcas1和Fas-L在妊娠早期的参与情况。RCAS1和Fas-L表达的减少与母体NK细胞的活化和浸润以及子宫腺体的破坏密切相关,导致胎儿排斥。子宫腺和细胞滋养细胞中RCAS1和Fas-L的表达可能起到下调母体免疫应答的作用,从而维持早期妊娠。我们的研究结果表明,RCAS1在肿瘤侵袭性的获得中起着重要作用。此外,RCAS1可能参与早期妊娠的维持。需要做以下工作:(1)鉴定RCAS1相关分子;(2)阐明RCAS1诱导细胞凋亡的分子机制;(3)明确Fas-L、TNF和RCAS1之间的不同功能。少
英文摘要
The functional and clinical significance of tumor-associated antigen, RCAS 1, was investigated in this study. RCAS1, one of type II membrane proteins, induces cell apoptosis in normal peripheral lymphocytes. RCAS1 is chromosomally localized to 8q23 and its expression is induced by estrogen. In our previous study, RCAS1 was strongly expressed in uterine and ovarian cancers and the expression of RCAS1 was strikingly correlated with poorprognosis in uterine cancer patients.(1) In order to clarify a biological role of RCAS1 in tumor behavior, we analyzed an association between RCAS1 expression and tumor stromal cell reaction by immunohistochemistry. In tumor metastatic lymph nodes, the apoptotic index of T lymphocytes significantly increased in uterine cancer patients with RCAS1 expression. In connective tissues surrounded tumor cells, cells with vimentin expression significantly decreased in patients with RCAS1 expression. But the expression of Fas-L or TNF-a was not associated with apoto … More tic index of T lymphocytes, and the number of cells with vimentin expression in connective tissues in the tumor stroma. On the basis of these findings, the expression of RCAS1 plays pivotal factors in the acquirement of tumor aggressiveness through the reduction of immune response and connective tissue reaction.(2) The relationship between RCAS1 expression and a progression of the uterine endometrial neoplasias was checked, the expression of RCAS1 was statistically higher in adenocarcinoma than in the normal and hyperplastic endometrium. Moreover, RCAS1 was statistically detected more frequently in grade 3 than in grade 1 or 2. These results indicated that RCAS1 expression might be associated with the malignant transformation and poor differentiation observed in uterine endometrial adenocarcinoma.(3) The involvement ofRCAS1 and Fas-L was studied in the early stage of pregnancy. A reduction in RCAS1 and Fas-L expression was suggested to be closely related with activation and infiltration of maternal NK cells and destruction of uterine glands, resulting in rejection of the fetus. The expression of RCAS1 and Fas-L in the uterine glands and cytotrophoblasts may play a role in the downregulation of the maternal immune response, thereby maintaining pregnancy at early stage.Our findings demonstrate that RCAS1 plays an important role in the acquirement of tumor aggressiveness. Moreover, RCAS1 might be involved in the maintenance of early pregnancy. Following works are necessary to be done: (1) to identify RCAS1 associated molecules, (2) to clarify molecular mechanisms for RCAS1 induced apoptosis, and (3) to make clear different functions among Fas-L, TNF and RCAS1. Less
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
K Sonoda, et al.: "The clinical significance of tumor-associated antigen RCAS1 expression in the normal hyperplastic and malignant uterine endometrium"Gynecologic Oncology. 79. 424-429 (2000)
K Sonoda 等人:“正常增生性和恶性子宫内膜中肿瘤相关抗原 RCAS1 表达的临床意义”妇科肿瘤学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
K.Sonoda et al.: "The Clinical Significance of Tumor-Associated Antigen RCAS1 Expression in the Normal, Hyperplastic, and Malignant Uterine Endometrium"Gynecologic Oncology. 79. 424-429 (2000)
K.Sonoda 等人:“正常、增生和恶性子宫内膜中肿瘤相关抗原 RCAS1 表达的临床意义”妇科肿瘤学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
K Ohshima, K Sonoda, et al.: "Expression of RCAS1 and Fas-L in human trophoblasts and uterine glands during pregnancy : the possible role in immune privilege"Clinical and Experimental Immunology. 123. 481-486 (2001)
K Ohshima、K Sonoda 等人:“怀孕期间人类滋养层和子宫腺体中 RCAS1 和 Fas-L 的表达:在免疫特权中的可能作用”临床和实验免疫学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
K Sonoda, et al.: "The clinical significance and function of tumor-associated antigen RCAS1"Proceedings : The 12th Fukuoka Internationl Symposium on Perinatal Medicine. 12. 66-69 (2001)
K Sonoda 等人:“肿瘤相关抗原 RCAS1 的临床意义和功能”论文集:第 12 届福冈国际围产期医学研讨会。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 7 条
    Nobel therapeutic strategy against human cancer by targeting RCAS1
    • 批准号:
      24592519
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2012
    • 负责人:
      SONODA Kenzo
    • 依托单位:
    Novel cancer therapeutic strategies to target RCAS1
    • 批准号:
      21592134
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2009
    • 负责人:
      SONODA Kenzo
    • 依托单位:
    Manufacture of novel RCAS1-targeting therapy against gynecologic cancer
    • 批准号:
      18591835
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.43万
    • 财政年份:
      2006
    • 负责人:
      SONODA Kenzo
    • 依托单位:
    The expression control and biofunctional analysis of RCAS1
    • 批准号:
      14571568
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2002
    • 负责人:
      SONODA Kenzo
    • 依托单位:
    国内基金
    海外基金
    Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
    • 批准号:
      LBY21H010001
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2020
    • 负责人:
      郑绪阳
    • 依托单位:
    去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
    • 批准号:
      31970691
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2019
    • 负责人:
      张胜萍
    • 依托单位:
    TM9SF4调控非小细胞肺癌细胞凋亡机制研究
    • 批准号:
      31900527
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2019
    • 负责人:
      孙磊
    • 依托单位:
    基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
    • 批准号:
      81703335
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2017
    • 负责人:
      卫高菲
    • 依托单位: